/TEVA
Teva Pharmaceutical Industries Limited
TEVA • NYSETEVA • NYSE • Healthcare
$32.91+1.95%+0.63
$32.91+1.95%(+0.63)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
82Bullish
Risk
91Low Risk
Momentum
80Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
51.8%▲3.1pp
Revenue after COGS
Operating
12.5%▲14.3pp
After operating expenses
Net
8.2%▲18.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
25.4
Price vs earnings
EV/EBITDA
15.8
Enterprise value
FCF Yield
3.2%
Cash generation
Earnings Yield
3.9%
Inverse of P/E
Capital Efficiency
10
GoAI Quality ScoreFair
ROEReturn on Equity
17.8%Strong
ROAReturn on Assets
3.5%Fair
ROICReturn on Invested Capital
7.4%Fair
Financial Health
Current RatioAdequate
1.04
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
4.40x
Debt repayment capacity (<3x)
Income QualityStrong
1.16
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Gross Profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B |
| Gross Margin | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% |
| Operating Income | $2.16B | -$303.00M | $433.00M | -$2.20B | $1.72B |
| Net Income | $1.41B | -$1.64B | -$559.00M | -$2.45B | $417.00M |
| Net Margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% |
| EPS | $1.23 | -$1.45 | -$0.50 | -$2.20 | $0.38 |
Average Price Target
$38.33▲ 16.5% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Teva Pharmaceutical Industries Limited, the average price target is $38.33, with a high forecast of $41.00 and a low forecast of $35.00. The average price target represents a 16.5% increase from the current price of $32.91.
Highest
$41.00
Average
$38.33
Lowest
$35.00
Rating Distribution
Strong Buy
0
0%
Buy
22
48%
Hold
20
43%
Sell
4
9%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Truist Securities● Maintain
Buy
2026-02-18Goldman Sachs● Maintain
Buy
2026-02-09Barclays● Maintain
Overweight
2026-01-30Scotiabank● Maintain
Sector Outperform
2026-01-29Truist Securities● Maintain
Buy
2026-01-29Jefferies● Maintain
Buy
2026-01-06Piper Sandler● Maintain
Overweight
2025-12-22Goldman Sachs● Maintain
Buy
2025-12-19JP Morgan● Maintain
Overweight
2025-12-16B of A Securities● Maintain
Buy
2025-12-09Earnings History & Surprises
BEAT RATE
67%
Last 18 quarters
AVG SURPRISE
+6.1%
EPS vs Estimate
BEATS / MISSES
12/4
2 met exactly
LATEST EPS
$0.96
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+47.7%
$0.96 vs $0.65
Q4 '25
+14.7%
$0.78 vs $0.68
Q3 '25
+4.8%
$0.66 vs $0.63
Q2 '25
+10.6%
$0.52 vs $0.47
Q1 '25
+2.9%
$0.71 vs $0.69
Q4 '24
+6.2%
$0.69 vs $0.65
Q3 '24
+7.0%
$0.61 vs $0.57
Q2 '24
-5.9%
$0.48 vs $0.51
Q1 '24
+33.3%
$1.00 vs $0.75
Q4 '23
$0.60 vs $0.60
Q3 '23
+3.7%
$0.56 vs $0.54
Q2 '23
-29.8%
$0.40 vs $0.57
No investor questions available.
Latest News
No news available